These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 26212044)

  • 41. Optimum combination therapy regimens for HIV/HCV infection.
    Rey D; Muret P; Piroth L
    Expert Rev Anti Infect Ther; 2016; 14(3):299-309. PubMed ID: 26822803
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Management and treatment of chronic hepatitis C in HIV patients.
    Barreiro P; Vispo E; Labarga P; Soriano V
    Semin Liver Dis; 2012 May; 32(2):138-46. PubMed ID: 22760653
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevention and management of treatment failure to new oral hepatitis C drugs.
    Benítez-Gutiérrez L; Barreiro P; Labarga P; de Mendoza C; Fernandez-Montero JV; Arias A; Peña JM; Soriano V
    Expert Opin Pharmacother; 2016 Jun; 17(9):1215-23. PubMed ID: 27149603
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.
    Meemken L; Hanhoff N; Tseng A; Christensen S; Gillessen A
    Ann Pharmacother; 2015 Jul; 49(7):796-807. PubMed ID: 25902733
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s.
    Kiser JJ; Lu D; Rosenkranz SL; Morse GD; DiFrancesco R; Sherman KE; Butt AA;
    Drugs R D; 2017 Dec; 17(4):557-567. PubMed ID: 28875397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of the Patient With HIV/Hepatitis C Drug Interactions: A Guide for Nurses and Nurse Practitioners.
    Starbird LE; Hong H; Sulkowski MS; Farley JE
    J Assoc Nurses AIDS Care; 2020; 31(2):241-248. PubMed ID: 31855873
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.
    Braun DL; Rauch A; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Metzner KJ; Böni J; Weber R; Fehr J
    HIV Med; 2014 Nov; 15(10):625-30. PubMed ID: 24894776
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of hepatitis B and hepatitis C coinfection: an expert review.
    Zarębska-Michaluk D; Flisiak R; Flisiak-Jackiewicz M
    Expert Rev Anti Infect Ther; 2020 Oct; 18(10):1033-1044. PubMed ID: 32579414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in an HIV-HCV-coinfected patient.
    Borentain P; Colson P; Dhiver C; Gregoire E; Hardwigsen J; Botta-Fridlund D; Garcia S; Gerolami R
    Antivir Ther; 2015; 20(3):353-6. PubMed ID: 25105441
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients.
    Jiménez-Nácher I; Alvarez E; Morello J; Rodriguez-Nóvoa S; de Andrés S; Soriano V
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):457-77. PubMed ID: 21342079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis C virus.
    Lai AR; Tashima KT; Taylor LE
    AIDS Patient Care STDS; 2006 Oct; 20(10):678-92. PubMed ID: 17052138
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era.
    Meissner EG
    Curr Opin Gastroenterol; 2017 May; 33(3):120-127. PubMed ID: 28234770
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current race in the development of DAAs (direct-acting antivirals) against HCV.
    De Clercq E
    Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient.
    Rodríguez-Torres M
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1117-28. PubMed ID: 23199398
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review of drug interactions with telaprevir and antiretrovirals.
    van Heeswijk RP; Beumont M; Kauffman RS; Garg V
    Antivir Ther; 2013; 18(4):553-60. PubMed ID: 23344266
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sofosbuvir as backbone of interferon free treatments.
    Bourlière M; Oules V; Ansaldi C; Adhoute X; Castellani P
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S212-20. PubMed ID: 25453869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs.
    Roncero C; Villegas JL; Martínez-Rebollar M; Buti M
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of new oral hepatitis C antiviral drugs.
    Vispo E; Barreiro P; Soriano V
    Expert Opin Drug Metab Toxicol; 2013 Jan; 9(1):5-16. PubMed ID: 23094639
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management.
    Jones M; Núñez M
    Curr Opin HIV AIDS; 2011 Nov; 6(6):546-52. PubMed ID: 22001896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.